Neurosteer

🌟 Have you ever seen a scientific experiment at a music festival? 🌟 This is exactly what we did at the Lithuanian Song Celebration! 🇱🇹🎶 In collaboration with Neurosteer and Indre Viskontas, we, Talya Zeimer and I, set up a tent in the heart of the festival’s beautiful park, and conducted mobile EEG brain examinations on 160 participants. Each underwent a 20-minute experiment, with musical tests designed to either challenge or relax frontal brain regions’ functionality. Our goal? To analyze their response to music, and explore correlations between age and engagement. As neurodegenerative disease cases rise, understanding the impact of music on brain function, especially in older adults, is crucial. Music engagement, particularly in social settings, may enhance frontal lobe function, which is critical for executive function and emotional regulation, while reducing stress. This 100th anniversary festival provided a unique and vibrant backdrop for our groundbreaking study. Thank you Dr. Ramunė Dirvanskienė for the invitation to this unique opportunity. Join us as we explore the fascinating intersection of neuroscience and music! 🎵🧠 #Neuroscience #MusicFestival #LithuanianSongFestival #MentalHealth #Neurosteer #EEG #BrainHealth #ScientificResearch

🎉 We are thrilled to announce the first 14 members to join StartUp Health’s Alzheimer's Moonshot Community, which was launched this year with support from Gates Ventures and the Alzheimer's Drug Discovery Foundation (ADDF). These inspiring founders and researchers span the spectrum from early detection to treatment to caregiver support and we’re already seeing the power of collaboration as we bring the community together. Meet them here ➡️ https://ow.ly/vlEi50RPqQC #AlzMoonshot #Alzheimers #HealthTransformers #HealthMoonshot ADmit Therapeutics, ALZpath Inc., C. Light Technologies, Inc., Ilios Therapeutics, Kernel, MindAhead, Moneta Health, Neurosteer, RetiSpec, Sinaptica Therapeutics, Stem Pharm, TELL Toolkit, ToxGenSolutions BV (TGS), Zinnia

תודה ל Globes גלובס שבחרו בי לנבחרת המנהיגות הצעירה של 2024 ״40 עד 40״ ואיפשרו להדהד את החזון שלי לגבי מוזיקה ומוח הלאה. https://lnkd.in/dvvdV3fe

Imagine a conductor's brainwaves seamlessly synchronizing with a cellist's and a listener's during a musical performance. This isn't science fiction—it's the reality captured by Neurosteer, featuring its new real-time neurofeedback technology. During the New World Symphony’s "By Ear, A Journey into Musical Perception" special concert in Miami Beach on March 21st, Neurosteer displayed the real-time brain activity of conductor Edwin Outwater, cellist Sarah, and Professor Indre Viskontas: a music neuroscientist who provided insights into how the brain engages with music throughout the concert, and invited us to participate in this fascinating exploration. The video revealed how three brain activity networks: default mode/resting state (blue), the executive control (green), and the salience/emotional network (red), achieved near-perfect synchronization by the piece's end. This real-time feedback is particularly valuable when brain network activity becomes disrupted, as in cases of anxiety, post-traumatic stress disorder, and neurodegeneration. Neurofeedback can then be used for diagnosis and training to help individuals regain control and improve their ability to switch between networks effectively during daily life. My deepest appreciation to Indre Viskontas, New World Symphony and Edwin Outwater for allowing me to participate in this wonderful concert, and letting the audience have a peek into musicians’ mind with Neurosteer.

Biogen's Decision to Dissolve Digital Health Division: Unpacking the Implications Biogen recently disbanded their digital health division, a notable 150-member team, choosing instead to lean into external technological solutions to drive their objectives forward. This development comes as a surprise, especially when considering Biogen's recent clearance for Leqembi, a novel drug poised to address early-stage Alzheimer’s by decelerating its progression. The now-disbanded digital health group had the mandate to innovate affordable diagnostic means to identify potential Alzheimer's patients who might benefit from Leqembi. Given Biogen's newly FDA-approved drug (a rare victory in the challenging landscape of neurodegenerative treatments), shuttering this division makes a significant statement. It suggests Biogen's recalibration of faith in digital health solutions, intimating a pivot toward exploring alternative diagnostic technologies. Ideal technology for early-stage Alzheimer's detection must satisfy three pivotal criteria: Affordability & Scalability: It must be cost-effective and capable of wide deployment. Proactive Identification: Capable of detecting potential Alzheimer’s at its latent, pre-symptomatic stages. Precise Diagnosis: Ensure accurate identification of Alzheimer’s. It's imperative, considering that nearly 40% of dementia cases are attributed to vascular, fronto-temporal, Lewy Body an other forms of dementia. Leqembi is specifically formulated for Alzheimer’s patients. Of note, a recently sanctioned blood test, which determines Alzheimer's risk based on an amyloid ratio, is restricted to patients already manifesting cognitive decline symptoms. It is not used in the critical early, pre-symptomatic phase. While this move might seem like a setback for the digital health realm, it potentially heralds a promising era for direct brain-analysis technologies, aimed at early detection and precise differentiation of Alzheimer’s. At Neurosteer, we're working diligently on tools that may help distinguish between different neurodegenerative disorders. Details about our ongoing research can be found in this preprint https://lnkd.in/dXNtME6k. #biogen #EEG #Neurosteer #Alzheimer's